September 9, 2024
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics to host investor call to review key data presented at ESMO on Monday, September 16, 2024, at 8:00 a.m.…
Pharmaceuticals, Biotechnology and Life Sciences
MacroGenics to host investor call to review key data presented at ESMO on Monday, September 16, 2024, at 8:00 a.m.…
Oslo, September 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the…
Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday,…
8 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to present updated clinical data on…
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as…
Trial Design Showcased for the MIST Study, a Recently Initiated Phase 2b Clinical Trial, Evaluating the Efficacy and Safety of…
CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial…
First time patients with LCA1 have been treated with gene therapy ATSN-101 demonstrated durable, clinically significant improvements in vision at…
FILSPARI (sparsentan) FILSPARI (sparsentan) FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of…